ERBB2 and breast carcinoma: Significantly, wehave shown that 22+ isactive against a range of cancer lines, being particularly activeagainst the therapeutically resistant A2780CIS ovarian cancer lineand the aggressive HER2-positive MCF7 breast cancer line.